A phase I/IIa trial of autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with stage III/IV ovarian cancer
Latest Information Update: 16 Apr 2017
Price :
$35 *
At a glance
- Drugs Tumour lysate particle-loaded dendritic cell vaccine Elios Therapeutics (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions; Therapeutic Use
- 16 Apr 2017 New trial record
- 05 Apr 2017 Results of 15 patients treated were presented at the 108th Annual Meeting of the American Association for Cancer Research